title: Reduction of liver stiffness by antiviral therapy in chronic hepatitis B.
abstract: BACKGROUND
  Liver stiffness (LS) has been reported to correlate with fibrosis stage (F). The correlation between LS and fibrosis stage and the reduction of LS by antiviral therapy were examined in patients with hepatitis B infection.
  
  
  METHODS
  LS was measured by FibroScan in 212 patients infected with hepatitis B virus. Liver biopsies were done in 51 patients. Changes of LS were assessed in 29 patients treated with nucleotide or nucleoside analogs and 52 patients without antiviral therapy.
  
  
  RESULTS
  LS was significantly correlated with fibrosis stage (ρ = 0.686, P < 0.0001). The optimal cut-off values of LS were 7.1 kPa for F ≥ 2, 10.7 kPa for F ≥ 3, and 16.0 kPa for F4. LS was significantly reduced by antiviral therapy, from 12.9 (range 6.2-17.9) kPa to 6.6 (4.4-10.3) kPa measured at an interval of 512 (range 366-728) days (P < 0.0001). Eleven of 19 (58%) patients with baseline fibrosis stages of F3-4 deduced from LS had 2-point or greater reductions of deduced stage at the last LS measurement. The change ratio of hyaluronic acid (P = 0.0390) was associated with a 2-point or greater reduction of deduced fibrosis stage. Without antiviral therapy, LS tended to increase, increasing from 6.1 (range 3.9-8.5) kPa to 6.3 (range 4.4-9.7) kPa at an interval of 422 (range 358-709) days (P = 0.0682).
  
  
  CONCLUSIONS
  LS was significantly correlated with fibrosis stage in patients with chronic hepatitis B. The reduction of LS by antiviral therapy was significantly correlated with the reduction of hyaluronic acid. Thus, we conclude that LS can be useful to assess the progression and regression of liver fibrosis stage noninvasively.
authors.affiliation: School of Health Sciences, Fujita Health University, Aichi, Japan.
authors.forename: Keisuke
authors.initials: K
authors.lastname: Osakabe
authors.forename: Naohiro
authors.initials: N
authors.lastname: Ichino
authors.forename: Toru
authors.initials: T
authors.lastname: Nishikawa
authors.forename: Hiroko
authors.initials: H
authors.lastname: Sugiyama
authors.forename: Miho
authors.initials: M
authors.lastname: Kato
authors.forename: Shiho
authors.initials: S
authors.lastname: Kitahara
authors.forename: Senju
authors.initials: S
authors.lastname: Hashimoto
authors.forename: Naoto
authors.initials: N
authors.lastname: Kawabe
authors.forename: Masao
authors.initials: M
authors.lastname: Harata
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Nitta
authors.forename: Michihito
authors.initials: M
authors.lastname: Murao
authors.forename: Takuji
authors.initials: T
authors.lastname: Nakano
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Shimazaki
authors.forename: Yuko
authors.initials: Y
authors.lastname: Arima
authors.forename: Koji
authors.initials: K
authors.lastname: Suzuki
authors.forename: Kentaro
authors.initials: K
authors.lastname: Yoshioka
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D001706:Biopsy; D018450:Disease Progression; D004548:Elasticity / Q000502:physiology*; D054459:Elasticity Imaging Techniques; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008099:Liver / Q000503:physiopathology*; D008103:Liver Cirrhosis / Q000503:physiopathology*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged
chemical_list: D000998:Antiviral Agents